Abstract

Acyclovir (ACV) and penciclovir (PNV) have been commonly used during the last few decades as potent antiviral agents, especially for the treatment of herpes virus infections. In the present research their binding properties with human serum albumin (HSA) were studied using different advanced spectroscopic and in-silico methods. The interactions between ACV/PNV and HSA at the three investigated temperatures revealed a static type of binding. Extraction of the thermodynamic parameters of the ACV-HSA and PNV-HSA systems from the measured spectrofluorimetric data demonstrated spontaneous interactions with an enthalpy change (∆H0) of −1.79 ± 0.29 and −4.47 ± 0.51 kJ·mol−1 for ACV and PNV, respectively. The entropy change (∆S0) of 79.40 ± 0.95 and 69.95 ± 1.69 J·mol−1·K−1 for ACV and PNV, respectively, hence supported a potential contribution of electrostatic binding forces to the ACV-HSA and PNV-HSA systems. Putative binding of ACV/PNV to HSA, using previously reported site markers, showed that ACV/PNV were bound to HSA within subdomains IIA and IIIA (Sudlow sites I and II). Further confirmation was obtained through molecular docking studies of ACV-HSA and PNV-HSA binding, which confirmed the binding site of ACV/PNV with the most stable configurations of ACV/PNV within the HSA. These ACV/PNV conformers were shown to have free energies of −25.61 and −22.01 kJ·mol−1 for ACV within the HSA sites I and II and −22.97 and −26.53 kJ·mol−1 for PNV in HSA sites I and II, with hydrogen bonding and electrostatic forces being the main binding forces in such conformers.

Highlights

  • Acyclovir (ACV), an acyclic analog of the innate nucleoside 2-deoxyguanosine (Figure 1), is very effective against a number of herpes groups in DNA viruses [1,2]

  • For over 3 decades, ACV has been considered a very potent and standard drug for the treatment of HSV-1 and HSV-2 (Herpes simplex virus 1 and 2); it is effective against some other viral infections such as the varicella–zoster virus

  • The interactions of the antiviral drugs, ACV and PNV, with the Human serum albumin (HSA) were explored by means of different spectroscopic tools with the determination of their binding parameters

Read more

Summary

Introduction

Acyclovir (ACV), an acyclic analog of the innate nucleoside 2-deoxyguanosine (Figure 1), is very effective against a number of herpes groups in DNA viruses [1,2]. For over 3 decades, ACV has been considered a very potent and standard drug for the treatment of HSV-1 and HSV-2 (Herpes simplex virus 1 and 2); it is effective against some other viral infections such as the varicella–zoster virus. ACV protects against cytomegalovirus in immunosuppressed patients undergoing organ transplantation [3,4]. There are many structural analogues of ACV; one of them is penciclovir (PNV). PNV is effective against the members of the herpes virus family [5]. Some studies have shown that PNV exerts the same effect on herpes viruses as ACV, but at a lower dose than

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.